Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group



Shaygannejad V1 ; Montazeri S2 ; Gharagozloo M3 ; Tahani S4 ; Ashtari F1 ; Vesal S5 ; Hasheminia SJ3 ; Dehghani L5
Authors

Source: Journal of Isfahan Medical School Published:2013

Abstract

Background: Midkine (MK) is a heparin-binding growth factor with various effects in induction of neurodegenerative diseases and promotes inflammatory responses by enhancing the migration of inflammatory leukocytes. This study aimed to determine the relationship of Midkine protein and clinical course of multiple sclerosis (MS). Methods: In 32 patients with MS and 32 Age- and sex-matched healthy people, the serum level of Midkine and other cytokines (IL10, IL17, IL23 and TGF-β) were determined by enzyme-linked immunosorbent assay (ELISA) method and compared. Findings: Midkine level in patients with MS was significantly lower than healthy control. In addition, there were significant differences between IL10, IL23 and TGF-β levels in patients with MS and the healthy people. Conclusion: It seems that the significant lower level of Midkine in patients with MS is because of IFN-β treatment for them during this research.
Related Docs
View other Related Docs
1. Correlation of Midkine Serum Level With Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis, Iranian Journal of Immunology (2014)
2. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
3. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (9)
Vahid Shaygannejad (8)
Other Related Docs
4. Assessment of the Impact of Interferon-ß and Rituximab on Nlrp3 and Aim2 Expression and Il-1Β Levels in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2025)
5. Evaluation of Plasma Osteopontin Level in Relapsing- Remitting Multiple Sclerosis Patients Compared to Healthy Subjects in Isfahan Province, International Journal of Neuroscience (2020)
6. Leptin Hormone Level in Serum of Opticospinal, Neuromyelitisoptica and Multiple Sclerosis Patients, Clinical and Experimental Neuroimmunology (2014)
7. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
8. Expression and Clinical Significance of Il7r, Nfatc2, and Rnf213 in Familial and Sporadic Multiple Sclerosis, Scientific Reports (2021)
9. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
10. Interleukin 18 Polymorphisms and Its Serum Level in Patients With Multiple Sclerosis, Annals of Indian Academy of Neurology (2019)
11. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
12. Association of Interleukin-1 Gene Cluster Polymorphisms and Haplotypes With Multiple Sclerosis in an Iranian Population, Journal of Neuroimmunology (2015)
13. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
14. Multiple Sclerosis and Cerebral Endothelial Dysfunction: Mechanisms, Pathophysiology (2011)
15. Evaluation of Matrix Metalloproteinase-9 Plasma Levels in Untreated New Relapsing–Remitting Multiple Sclerosis Patients and Their First-Degree Family, Metabolic Brain Disease (2021)
16. Tnf-Alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls, Immunological Investigations (2015)
17. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial, International Immunopharmacology (2021)
18. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
19. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
20. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, Iranian Journal of Immunology (2014)